Healthcare AI · Agent Unfolded

Abridge

AI-Powered Clinician Intelligence and Clinical Documentation Platform

Pittsburgh, Pennsylvania, United States

Abridge develops AI technology that transforms patient-clinician conversations and medical records into structured clinical documentation, contextual insights and actionable workflows. Its platform supports clinicians before, during and after patient encounters, with applications across documentation, clinical decision support, coding and revenue-cycle operations.

Official website abridge.com ↗
Abridge company logo

Company logo: Abridge official website

Company overview

Abridge is a healthcare technology company building generative AI systems for clinical conversations. Its initial product addressed a major administrative challenge in healthcare: the time clinicians spend documenting patient encounters in electronic health records.

The platform captures patient-clinician conversations and generates structured clinical notes for clinician review. Abridge’s technology is designed to connect generated documentation to the underlying conversation through Linked Evidence, allowing clinicians to verify where information in a note came from.

Since its launch, Abridge has expanded beyond ambient documentation. Its broader clinician intelligence platform connects patient history, real-time clinical conversations, medical evidence, documentation, coding and reimbursement workflows.

Founded in 2018, Abridge is headquartered in Pittsburgh, Pennsylvania, and operates across major healthcare markets in the United States.

Products and technology

Ambient clinical documentation: Abridge captures patient-clinician conversations and converts them into structured clinical notes. Clinicians can review, edit and approve the generated documentation before it is added to the electronic health record.

Contextual Reasoning Engine: The platform uses clinical context, prior patient information, clinician preferences and health-system guidance to generate more relevant documentation and support clinical workflows.

Linked Evidence: Generated note content can be traced back to the source conversation and supporting information. This helps clinicians review and verify AI-generated documentation rather than relying on an unreferenced summary.

Pre-visit intelligence: Abridge can summarize relevant patient history, previous encounters and care gaps before a visit, helping clinicians prepare without manually reviewing multiple records.

Clinical decision support: The platform brings patient context together with trusted medical evidence. Its content partnerships include NEJM Group and the American Medical Association’s JAMA Network, enabling evidence-based insights within clinical workflows.

Clinical coding and revenue-cycle workflows: Abridge supports documentation specificity, billing-related outputs and coding workflows. Its September 2026 pre-bill review capability helps clinical documentation integrity and coding teams compare inpatient diagnoses and DRGs with the clinical documentation before claims are submitted.

Inpatient and outpatient workflows: The platform supports multiple care settings, including outpatient visits, emergency medicine and inpatient care. It can assist with pre-round summaries, progress notes, discharge documentation and related clinical workflows.

Electronic health record integrations: Abridge integrates into existing clinical workflows, including Epic, Oracle Health and athenahealth. Its Epic integration allows clinicians to capture conversations and review generated documentation within their established EHR environment.

Multilingual and specialty support: Abridge reports support for more than 28 languages and a broad range of medical specialties and care settings.

Funding history

Abridge has raised several rounds of venture funding to expand its clinical AI platform and enterprise healthcare deployments. Its largest publicly announced round was a $300 million Series E in June 2025, led by Andreessen Horowitz.

Round Amount Announced Lead investor
Seed Approximately $5.3 million January 2019 Early investors
Series A Approximately $10.2 million October 2020 Early investors
Series A-1 Approximately $12.5 million August 2022 Existing investors
Series B $30 million October 2023 Not consistently identified in public round summaries
Series C $150 million February 2024 Lightspeed Venture Partners and Redpoint Ventures
Series D $250 million February 2025 Elad Gil and IVP
Series E $300 million June 2025 Andreessen Horowitz

Abridge announced its Series C funding in February 2024, led by Lightspeed Venture Partners with Redpoint Ventures as co-lead. The round also included IVP, Spark Capital, Union Square Ventures, Bessemer Venture Partners, Wittington Ventures, Kaiser Permanente Ventures, CVS Health Ventures and Mass General Brigham’s AI and Digital Innovation Fund.

In February 2025, Abridge announced a $250 million Series D co-led by Elad Gil and Institutional Venture Partners. Bessemer Venture Partners, California Health Care Foundation, CapitalG, CVS Health Ventures and other investors participated.

The company announced its $300 million Series E in June 2025, led by Andreessen Horowitz, with Khosla Ventures joining the round. Third-party financing databases also identify NVentures, Bessemer Venture Partners, Eli Lilly and other investors among the Series E participants.

Abridge also announced a strategic investment from Eli Lilly in June 2026. The investment amount was not disclosed, so it is not included in the funding total shown here.

Funding and valuation note: Adding the disclosed round amounts in the table gives approximately $758 million. Third-party databases report totals ranging around $764 million to $774 million, depending on their treatment of financing records and extensions. The last clearly disclosed round valuation was $5.3 billion in June 2025. Later implied or secondary-market estimates are not confirmed company valuations.

Founders and leadership

Shiv Rao, MD · Co-Founder and CEO: Shiv Rao is a practicing cardiologist and the company’s chief executive officer. He helped establish Abridge around the idea that patient-clinician conversations contain valuable information that can improve documentation, clinical understanding and healthcare operations.

Sandeep Konam · Co-Founder: Sandeep Konam is one of Abridge’s co-founders and helped build the company’s technology and early product foundations.

Florian Metze · Co-Founder: Florian Metze is a speech and language technology researcher whose work has contributed to Abridge’s focus on understanding clinical conversations.

Zachary C. Lipton · Co-Founder and AI Researcher: Zachary Lipton is a machine learning researcher associated with Abridge’s scientific and technical foundations. He has published research on machine learning, healthcare and AI evaluation.

San Oo · Chief Technology Officer: San Oo leads technology at Abridge, focusing on building secure, reliable products and platforms for healthcare organizations.

Brian Wilson · Chief Commercial Officer: Brian Wilson leads commercial activities and works with healthcare organizations adopting Abridge’s platform.

Janie Lee · Vice President, Product: Janie Lee leads product work focused on improving healthcare delivery through Abridge’s technology.

Investors

Abridge has attracted venture capital firms, healthcare organizations and strategic investors. Its funding syndicate includes investors with experience in enterprise software, healthcare technology, AI research and health-system operations.

Andreessen HorowitzSeries E lead investor
Lightspeed Venture PartnersSeries C lead investor
Redpoint VenturesSeries C co-lead investor
Institutional Venture PartnersSeries D co-lead investor
Bessemer Venture PartnersParticipating investor
Spark CapitalParticipating investor
Union Square VenturesParticipating investor
CapitalGParticipating investor
NVenturesNVIDIA venture investment arm
Eli Lilly and CompanyStrategic investor
CVS Health VenturesHealthcare strategic investor
Kaiser Permanente VenturesHealthcare strategic investor

Other investors and participants reported across Abridge’s financing history include Khosla Ventures, Wittington Ventures, California Health Care Foundation, Mass General Brigham’s AI and Digital Innovation Fund, Emerson Collective, Catalio Capital Management and Elad Gil.

Customers and market traction

Abridge has grown its presence across large and complex healthcare systems in the United States. In its June 2025 Series E announcement, the company said it was partnering with more than 150 enterprise health systems and expected its platform to support clinicians across more than 50 million medical conversations during that year.

By 2026, Abridge reported that its platform was used by more than 300 health systems and supported over 100 million patient-clinician conversations annually. Its partner organizations include major health systems and healthcare providers such as Mayo Clinic, Kaiser Permanente, Johns Hopkins, Duke Health, UNC Health, Inova and Memorial Sloan Kettering Cancer Center.

Abridge also reports adoption across more than 55 specialties and support for 28 or more languages. Its customer stories highlight improvements in documentation effort, clinician satisfaction and cognitive load, although individual results vary by health system and implementation.

The company’s growth reflects a shift from standalone medical transcription tools toward enterprise AI systems integrated into clinical and financial workflows.

Traction disclosure: Deployment counts, conversation volumes, specialty coverage and customer outcome figures are based on company announcements and partner materials. They are not independently audited market-wide measurements.

Strategic partnerships and ecosystem

NVIDIA: Abridge and NVIDIA announced a collaboration in June 2026 to develop a foundation model purpose-built for clinical conversations. The project uses NVIDIA AI infrastructure and the Nemotron model family as part of Abridge’s work on domain-specific clinical AI.

NEJM Group and JAMA Network: Abridge announced content partnerships with NEJM Group and the American Medical Association in April 2026. These partnerships bring peer-reviewed medical research into the platform’s clinical decision support workflows.

American Health Information Management Association: Abridge is working with AHIMA to support the quality, accuracy and auditability of its clinical coding and documentation improvement capabilities.

Availity: Abridge has partnered with Availity to support AI-powered prior authorization workflows, with the aim of connecting clinical documentation to payer processes.

These partnerships extend Abridge’s position beyond note generation into clinical evidence, reimbursement and healthcare workflow coordination.

Security, compliance and responsible AI

Abridge positions security, privacy and clinical review as core parts of its enterprise platform. Its company materials describe HIPAA-compliant operations, encrypted data in transit and at rest, secure U.S.-based cloud infrastructure, single sign-on and configurable governance controls.

Linked Evidence is a key part of the company’s approach to AI accountability. It allows clinicians to connect generated documentation to source information, making it easier to check and correct outputs.

Abridge’s workflows keep clinicians involved in reviewing and approving documentation and clinical actions. The platform is designed to support clinical judgment rather than independently replace it.

Frequently asked questions

What does Abridge do?

Abridge develops healthcare AI software that transforms patient-clinician conversations and medical records into structured clinical notes, summaries and actionable insights. Its platform also supports clinical decision support, coding and revenue-cycle workflows.

When was Abridge founded?

Abridge was founded in 2018. The company is headquartered in Pittsburgh, Pennsylvania, United States.

Who founded Abridge?

Abridge’s founding team includes Shiv Rao, Sandeep Konam and Florian Metze, with Zachary C. Lipton also identified in third-party company profiles as a co-founder. Shiv Rao is the company’s CEO.

How much funding has Abridge raised?

Abridge announced a $300 million Series E in June 2025. Adding the disclosed amounts across its publicly tracked rounds gives approximately $758 million, while third-party databases report totals in the $764 million to $774 million range depending on included financing records.

What is Abridge’s valuation?

Abridge’s last clearly disclosed funding valuation was $5.3 billion in June 2025, when it raised its $300 million Series E. Later third-party implied valuations are estimates and should not be treated as a confirmed company valuation.

Who are Abridge’s investors?

Investors include Andreessen Horowitz, Lightspeed Venture Partners, Redpoint Ventures, IVP, Bessemer Venture Partners, Spark Capital, Union Square Ventures, CapitalG, CVS Health Ventures, Kaiser Permanente Ventures, NVentures and Eli Lilly, among others.

Which healthcare systems use Abridge?

Publicly identified health-system partners include Mayo Clinic, Kaiser Permanente, Johns Hopkins, Duke Health, UNC Health, Inova and Memorial Sloan Kettering Cancer Center.

Does Abridge integrate with electronic health records?

Yes. Abridge integrates into healthcare workflows and identifies Epic, Oracle Health and athenahealth among its EHR integrations.

Corrections or updates? If you spot an error or have information that should be updated in this profile, please contact hello@agentunfolded.com.

← Explore the AI Startup Directory
Scroll to Top